Reactive arthritis sits in a gray zone. It’s not a classic autoimmune disease like lupus or rheumatoid arthritis, but the joint inflammation it causes is driven by an immune system that has turned against the body’s own tissues. Most experts classify it as an “autoimmune-related” or “immune-mediated” condition, specifically a type of spondyloarthropathy, triggered by an infection elsewhere in the body.
The distinction matters because it shapes how the condition is treated, how long it lasts, and what you should expect.
Why the Classification Is Complicated
In a textbook autoimmune disease, the immune system attacks the body’s own tissues on an ongoing basis, often without a clear external trigger. Reactive arthritis works differently. It starts with a real bacterial infection, usually in the gut or urinary tract, and the joint inflammation develops days to weeks later as a misdirected immune response to that infection. The bacteria themselves don’t typically invade the joints.
The mechanism behind this is called molecular mimicry. Certain proteins on the surface of triggering bacteria look structurally similar to proteins found in human joint tissue. When the immune system produces antibodies and immune cells to fight the infection, those same defenders can mistakenly recognize the body’s own joint lining as foreign. This cross-reactivity recruits inflammatory cells to the joints, causing swelling, pain, and damage even though the original infection may already be clearing. In this sense, the immune response is genuinely autoimmune in nature. It’s attacking self. But unlike rheumatoid arthritis, which persists indefinitely, reactive arthritis is usually self-limiting, resolving within 3 to 12 months.
The Bacteria That Set It Off
Five bacterial species account for most cases: Salmonella, Yersinia, Campylobacter, and Shigella (all gut infections, often from contaminated food or water) and Chlamydia (a sexually transmitted infection). Only a small percentage of people infected with these bacteria ever develop reactive arthritis. Most recover from the infection without joint problems.
What separates those who develop it from those who don’t comes down partly to genetics. People who carry a gene variant called HLA-B27 are significantly more likely to develop reactive arthritis after one of these infections. Research has also found that HLA-B27 carriers tend to have less diverse gut bacteria overall, and the degree of this imbalance correlates directly with symptom severity.
Symptoms Beyond Joint Pain
Reactive arthritis was historically known as Reiter’s syndrome and described as a classic triad: joint inflammation, eye inflammation (conjunctivitis), and urinary tract inflammation (urethritis). In practice, only about one third of patients actually show all three symptoms. Most present with just one or two.
The arthritis itself tends to hit the knees, ankles, and feet asymmetrically, meaning one side of the body is affected more than the other. Swelling can be dramatic, particularly in the toes or fingers, which may puff up into what’s sometimes called “sausage digits.” Eye redness and pain, burning during urination, skin rashes on the palms or soles, and mouth sores can all accompany the joint symptoms. Because the presentation varies so widely, diagnosis can take time.
How It’s Treated
Treatment focuses on controlling the immune-driven inflammation rather than fighting the original infection. Prescription anti-inflammatory medications are the first step, reducing swelling and pain in the affected joints. Steroid injections directly into a swollen joint can provide faster relief for severe flares, and steroid eye drops or skin creams address symptoms in those areas.
If symptoms persist beyond a few months, stronger immune-modulating medications originally developed for rheumatoid arthritis may be introduced. These work by dialing down the overactive immune response that’s driving the inflammation.
One surprising finding: antibiotics don’t reliably help the joint symptoms. A systematic review of seven clinical trials involving 375 participants found no significant benefit of antibiotic treatment on achieving remission, regardless of whether the triggering infection was chlamydia or a gut bacterium. Antibiotics were, however, associated with a near-doubling of gastrointestinal side effects. If the original infection is still active, antibiotics treat that infection specifically, but they don’t appear to shut down the immune process already underway in the joints.
Long-Term Outlook
Most people recover fully. The condition typically clears within 3 to 12 months, and many people never experience it again. This self-limiting nature is one of the main reasons reactive arthritis isn’t grouped with chronic autoimmune diseases.
A small percentage of people, however, develop a more persistent form that transitions into chronic spondyloarthritis, with ongoing joint inflammation that can cause real structural damage over time. These are the cases where long-term immune-modulating treatment becomes necessary. Carrying the HLA-B27 gene appears to increase this risk, though it doesn’t guarantee a chronic course.
If your joint symptoms haven’t improved after several months, or if they keep returning after apparent recovery, that pattern suggests the immune response has become self-sustaining rather than infection-driven, moving the condition closer to a true autoimmune process.